Table 1.
Demographic and clinical data.
| Population characteristics | Years/ kg/m2 | (range) | Patient identification, sample number |
|---|---|---|---|
| Age, median years (min-max) | 71 | (53–85) | |
| BMI, median kg/m2 (min-max) | 27 | (21–40) | |
| BMI ≥ 30 | 5 | 4, 5, 10, 21, 29 | |
| BMI ≥ 40 | 1 | 29 | |
| Population characteristics | Number of patients | (%) | Patient identification, sample number |
| Sex, male | 21 | (78) | |
| Sex, female | 6 | (22) | 9, 13, 14, 15, 16, 20 |
| Neoadjuvant chemotherapy | 8 | (29) | |
| MVAC | 5 | (19) | 3, 9, 14, 20, 28 |
| GC | 3 | (11) | 10,11,16 |
| Antibiotic prophylaxis | 27 | (100) | |
| quinolone + metronidazole | 25 | (93) | |
| trimethoprim sulfa + metronidazole | 1 | (4) | 13 |
| furadantin + metronidazole | 1 | (4) | 18 |
| Indication, bladder cancer | 24 | (88) | |
| Indication, prostate cancer | 2 | (7) | 2, 27 |
| Indication, chronic cystitis | 1 | (4) | 15 |
| Chronic diseases none | 5 | (19) | 8, 11, 14, 18, 30 |
| Chronic diseases yes | 22 | (81) | |
| Diabetes mellitus 2 | 2 | (7) | 10, 22 |
| Cardiovascular disease* | 15 | (56) | 1, 2, 3, 4, 5, 9, 10, 13, 16, 19, 20, 22, 23, 24, 28 |
| COPD/Asthma | 5 | (19) | 5, 6, 12, 28, 29 |
| Irritable bowel disease | 1 | (4) | 20 |
| Constipation | 1 | (4) | 28 |
| Cancer coli operata | 1 | (4) | 6 |
| Regular medications, none | 5 | (19) | 8, 11, 14, 18, 30 |
| Regular medications, yes | 22 | (81) | |
| Statins | 15 | (56) | 1, 2, 4, 5, 10, 13, 16, 19, 21, 22, 24, 26, 27,28, 29 |
| PPI | 3 | (11) | 3, 26, 27 |
| Antidiabetics | 2 | (7) | 10, 22 |
| Antibiotics prior to admission (last week) | 5 | (19) | 11, 13, 15, 16, 19 |
| Antibiotics prior to admission (last six months) | 15 | (56) | 1, 2, 9, 11, 12, 13, 14, 16, 18, 19, 20, 26, 28, 29, 30 |
BMI: body mass index, MVAC: Methotrexate, vinblastine, neomycin (Adriamycin), cisplatin. GC: Gemcitabine, cisplatin. COPD: Chronic Obstruction Pulmonary Disease, *including hypercholesterolemia and hypertension